Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Chief: ‘Safety Is Our Priority’ In Review Of COVID-19 Vaccine

Data To Be Made Available Quickly After Approval

Executive Summary

The EMA says its experts are working “around the clock” on a recommendation for conditional marketing authorization of a COVID-19 vaccine, but that it will only OK a vaccine if it is satisfied that the evidence convincingly shows the benefits are greater than the risks.

You may also be interested in...



Russians Attack 'Negative' EMA Comments On National Sputnik V Authorizations

Politics are never far from the surface where coronavirus vaccines are concerned, as demonstrated by recent comments by the Sputnik V developers. 

EU ‘Ready To Approve’ COVID-19 Vaccine On 23 December

European parliamentarians have defended the formal marketing authorization approach being taken by the EU, saying “safety is of the utmost importance” if there is to be trust in coronavirus vaccines.

EMA COVID-19 Vaccine Data Hack: UK Cybersecurity Body Probes Impact

The cyberattack on coronavirus vaccine data held by the European Medicines Agency is the latest in a string of hacks that are also targeting organizations involved with the cold chain distribution of vaccines.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel